Astex selects PharmaVentures to assist in divesment of CMC & Formulation Facility

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

Dr Fintan Walton, CEO, PharmaVentures commented, "We are delighted to have been chosen by Astex to assist in divesting this state-of-the-art facility, maximising return for the stakeholders.  With 20 years' experience of transactions, PharmaVentures can provide Astex with access to key decision makers in relevant companies with a view to safeguarding the future of the site."